Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings.
Atsuho MoritaHo NamkoongKazuma YagiTakanori AsakuraMakoto HosoyaHiromu TanakaHo LeeTakunori OgawaTatsuya KusumotoShuhei AzekawaKensuke NakagawaraHirofumi KamataMakoto IshiiKoichi FukunagaHiroyuki OzawaNaoki HasegawaPublished in: Infection and drug resistance (2022)
ALIS therapy might be a treatment option for patients with refractory MAC infection with long disease duration and a poor response to guideline-based therapy.